Anteris Technologies Global Corp. filings document the regulatory record of a structural heart medical device issuer developing the DurAVR® Transcatheter Heart Valve for aortic stenosis. Its reports and material-event filings cover operating and financial results, Form 10-K disclosures, clinical and regulatory activity tied to the PARADIGM trial, research and development spending, risk factors and management discussion of liquidity and operations.
The company’s SEC filings also describe material agreements, facility leases, strategic investment and public offering activity, common-stock capital structure, registration statements, equity incentive awards, director and officer governance matters, subsidiary arrangements and disclosures furnished for ASX reporting. These documents connect AVR’s device-development program with financing, governance and public-company reporting obligations.
L1 Capital Pty Ltd, a more than 10% holder of Anteris Technologies Global Corp., reported indirect open-market purchases. On 2026-01-22 it bought 5,000,000 common shares at $5.75, bringing indirect holdings to 7,812,000 shares. A prior 2025-10-28 trade added 1,333,334 CHESS Depository Interests at $4.935, each exchangeable for one common share within 60 days, for 5,407,814 CDIs held indirectly through L1-managed funds.
L1 Capital Pty Ltd, reported as a 10% owner of Anteris Technologies Global Corp., reported two indirect sales by funds it controls. On 24 July 2026 they sold 23,000 common shares at $8.13, leaving 7,789,000 shares. On 27 July 2026 they sold 48,344 CHESS Depository Interests at $8.15, leaving 5,359,470, with each CDI representing one underlying common share exchangeable within 60 days. L1 Capital states it does not admit being obligated to file ownership reports because it believes it is exempt under Rule 16a-2.
Anteris Technologies Global Corp. filed a Form S-3 prospectus registering up to 5,385,000 shares of common stock (including 3,038,064 CDIs) to be issued upon exercise of outstanding warrants. The registration covers 2,346,936 Common Stock Warrant shares (exercise price $7.50) and 3,038,064 CDI Warrant Shares (exercise price A$11.50).
The prospectus states the company would receive proceeds if and when holders exercise the Warrants — up to approximately $42.1 million in aggregate, comprised of $17.6 million from Common Stock Warrants and approximately A$22.8 million from CDI Warrants. It discloses 97,232,054 shares outstanding as of March 31, 2026 and includes dilution tables showing per-share dilution calculations as of that date.
Anteris Technologies Global Corp. director Gregory S. Moss exercised restricted stock units into common shares as part of his equity compensation. On June 7, 2026, 17,580 restricted stock units converted into 17,580 shares of common stock at a stated price of $0.00 per share, reflecting a non-cash vesting event rather than a market purchase. Following the transaction, he directly held 17,580 common shares, and 35,162 restricted stock units were reported as remaining outstanding from a 52,742-unit grant awarded on December 3, 2025 that vests in approximately equal installments on June 7, 2026, June 7, 2027, and June 7, 2028, subject to continued service.
Anteris Technologies Global Corp. director David B. Roberts exercised restricted stock units into common stock as part of his equity compensation. On June 7, 2026, he converted 17,580 RSUs into 17,580 shares of common stock at a stated price of $0.00, and now holds 17,580 common shares directly. These RSUs are from a December 3, 2025 grant of 52,742 RSUs that vest in roughly equal installments on June 7, 2026, 2027, and 2028, leaving 35,162 RSUs outstanding after this vesting event.
Anteris Technologies Global Corp. Chief Financial Officer Matthew McDonnell reported a compensation-related options exercise and associated tax withholding. Through the McDonnell Family Trust, he exercised stock options for 62,001 shares of common stock at exercise prices of $6.32 and $4.84 per share, receiving CHESS Depositary Interests traded on the ASX. Of these, 39,595 shares were delivered to cover tax obligations, a non–open-market disposition. Following these transactions, he holds 27,777 shares directly and 22,406 shares indirectly through the trust.
Anteris Technologies Global Corp. director Susan Elizabeth Knight reported an open-market purchase of the company’s Common Stock. She bought 11,000 shares on June 2, 2026 at a weighted average price of $9.2935 per share, bringing her direct holdings to 11,000 shares.
According to a footnote, the purchase consisted of 5,000 shares at $9.31 per share and 6,000 shares at $9.2797 per share.
Anteris Technologies Global Corp. entered into a Sales Agreement with TD Securities (USA) LLC on May 22, 2026 to sell shares of its common stock in an at-the-market offering with an aggregate offering price of up to $250,000,000 through TD Cowen. This prospectus supplement dated May 26, 2026 updates the Registration Statement and Prospectus related to up to 9,103,796 shares of common stock that may be offered by selling stockholders and attaches the Form 8-K describing the Sales Agreement.
The Sales Agreement permits sales on Nasdaq, negotiated transactions and block trades, and sets TD Cowen’s selling commission at 3.0% of gross proceeds. Net proceeds are intended primarily for development of the DurAVR® Transcatheter Heart Valve System and for working capital and general corporate purposes.
Anteris Technologies Global Corp. entered into a Sales Agreement with TD Securities (USA) LLC (TD Cowen) to establish an at-the-market stock offering program. The company may, at its discretion, sell shares of common stock with an aggregate offering price of up to $250,000,000 through TD Cowen as agent or principal.
Sales can be made over time on Nasdaq or through negotiated block trades, with TD Cowen earning a 3.0% commission on gross proceeds from shares it sells as agent. Anteris currently plans to use any net proceeds primarily to fund development of its DurAVR® Transcatheter Heart Valve System, and the remainder for working capital and general corporate purposes.
Anteris Technologies Global Corp. filed a prospectus supplement establishing an at-the-market offering program to sell up to $250,000,000 of its common stock through TD Securities (USA) LLC (TD Cowen) as sales agent. Sales may occur from time to time on Nasdaq or other trading venues; TD Cowen will receive 3.0% of gross proceeds as compensation.
The supplement uses an example price of $9.00 per share (last reported sale on May 21, 2026) and illustrates issuance of 27,777,777 shares, resulting in up to 125,009,831 shares outstanding under that example. Net proceeds are intended primarily for continued development of the DurAVR® THV System, with remaining amounts for working capital and general corporate purposes.